Brind.

Leerink partners reiterated a Buy rating on the stock of MannKind Corporation on August 26, 2025.

2 reports, 1 independent Updated Aug 26

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Leerink partners reiterated a Buy rating on the stock of MannKind Corporation on August 26, 2025.

Who's involved

What this event is mainly about

Leerink partners MannKind Corporation

Keep exploring

The entities involved

Leerink partners
U.S. investment bank
- Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Sun 19:40
- Intuitive Surgical received a Buy rating from Leerink partners, citing increased da Vinci placements and potential benefits from Trump-era tariffs.Sat 07:31
MannKind Corporation
biopharmaceutical company

Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped

Aug 26Insider MonkeyLeerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7 MannKind Corporation (NASDAQ:MNKD) is one of the top strong buy stocks under $5 to buy now. On August 8, Le
Aug 23Insider MonkeyLeerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT MannKind Corporation (NASDAQ:MNKD) is one of the Most Oversold Penny Stocks to Buy Now. On August 6, Faisal Khurshid fro